REVISION 2 Molecular Pathways: Digoxin use and estrogen...
Transcript of REVISION 2 Molecular Pathways: Digoxin use and estrogen...
1
REVISION 2 Molecular Pathways: Digoxin use and estrogen-sensitive cancers: risks and possible
therapeutic implications
Invited review
Robert J. Biggar Department of Epidemiology Research
Statens Serum Institut Copenhagen, Denmark
Running Title: Digoxin and estrogen-sensitive cancer risk
Address for correspondence:
Robert J. Biggar, MD
Department of Epidemiology Research, Statens Serum Institut
Artillerivej 5, 2300 Copenhagen, Denmark
Email: [email protected]
Phone: (45) 3268 3722
The author declares no conflict of interest. The study was a review requiring no ethical approval.
All work is original and not submitted for consideration elsewhere.
Abstract: 199 words; Text: 2,177 words; Tables: 0; Figures: 1; References: 66.
Key words:
Digoxin, digitalis, estrogen, spironolactone, gynecomastia, breast cancer, uterus cancer,
endometrial cancer, ovary cancer, ovarian cancer, cervical cancer, prostate cancer, estrogen
receptors, tamoxifen, aromatase inhibitors
Key words not in abstract:
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
2
Endometrial cancer, ovarian cancer, cervical cancer, digitalis, gynecomastia Abstract Digoxin, a phyto-estrogen, binds with estrogen receptors (ERs) and can cause gynecomastia.
Among women currently using digoxin, breast and uterus cancers incidences are significantly
increased (approximate risk ratios: 1.3 to 1.5). Both cancers are often estrogen-sensitive. In
contrast, ovary and cervix cancers are relatively estrogen-insensitive, and incidence is unaffected
by digoxin exposure. When digoxin use stops, incidence rapidly reverts to that in non-uses.
These patterns parallel those of estrogen, suggesting that digoxin works via ER-stimulated
proliferation of ductal/acinar cells, accelerating the growth of nascent cancers. Also consistent
with an estrogenic effect, men using digoxin have a small but significant reduction in prostate
cancer (risk ratio: 0.76). Other estrogen-like drugs, particularly spironolactone, should be
investigated for similar effects. The effect of digoxin use in women being treated for breast
cancer or in survivors is unknown. Women with estrogen-sensitive cancers on adjuvant therapy
may take tamoxifen, which blocks ERs. However, post-menopausal patients may use aromatase
inhibitors, which block estrogen production while leaving ERs susceptible to digoxin. If adverse
effects are found, tamoxifen may be preferred over aromatase inhibitors in patients receiving
estrogen-mimicking drugs. Alternatively, other cardiotropic drugs might be considered in
women with or at high risk of developing estrogen-sensitive cancers.
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
3
BACKGROUND
Digitalis, a medicinal extract of the plant foxglove, has a powerful inotropic effect on cardiac
muscle. Chemically, two forms are used as medications in patients with heart disease, digoxin
and, less commonly, digitoxin. Both forms are phyto-estrogens, or plant estrogens. Recent
studies have shown that use of digoxin significantly increases the risk of breast and uterus
cancer1-3. Both cancers are often estrogen-sensitive. In contrast, no changes in risk were seen
for two ovary and cervix3 cancers, both relatively estrogen-insensitive.
Chemistry and physiology
The principal effect of digitalis drugs is to inhibit the sodium-potassium pump, which regulates
the flux of ions across the cell membrane, calcium being of particular importance in cardiac
conditions4. However, the basic structure of digitalis compounds is similar to that of estradiol,
the principal estrogen (Figure 1). Several studies have indicated that digitalis drugs have the
capacity to bind to estrogen receptors (ERs), although with less affinity than estrogen itself5,6.
Stimulation of ERs induces proliferation of ductal and acinar tissue. Thus, it is not surprising
that chronic use of digitalis induces gynecomastia in men7,8, just as will estrogen excess in men.
The effect on female breast tissue is likely similar, although enlargement would be less
noticeable.
Estrogen and cancer risk
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
4
The vast literature on estrogen use and cancer risks in women is beyond the scope of this review.
Briefly, exogenous estrogens given as menopausal hormone therapy have been documented to
increase the incidence of breast cancer in many studies see reference 9, particularly when given with
progestins10. Generally, breast cancer incidence increases soon after initial exposure remained
above expected levels for the duration of use, possibly increasing slightly over time. However,
when estrogen exposure ceases, the incidence of breast cancer promptly declines as well. This
pattern is consistent with a pathway in which current use of estrogen accelerates the growth of
nascent breast cancers rather than inducing them de novo11. Similarly, for the uterus, both
hyperplasia12 and endometrial cancer incidence13 increase with estrogen use, an effect decreased
by including progestins in the formulation of hormone therapy. For ovary cancer, there appears
to be a slight increase in risk with estrogen use14-16 but not to the risk ratios seen with breast
cancer. Use seems not to impact cervical cancer risk17.
Digitalis and cancer risk
The potential for digitalis to increase cancer risk was appreciated decades ago. Three studies
specifically examined this hypothesis, all concluding there was no significant increase in risk18-
20. However, in each study, the point estimate of incidence was increased about 30% above non-
users. With hindsight, there was inadequate power to detect low risks with statistical confidence,
given their limited size. In two case-control studies, men with breast cancer were significantly
more likely (2-fold) to use digitalis than expected21,22. These studies ignored or dismissed the
importance of these associations.
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
5
Recently, two studies in Denmark re-examined breast cancer risk in women using digoxin1,2, the
only digitalis drug in the Danish formulary. Using large datasets, both studies reached similar
conclusions: the risk was significantly increased. In a regional case/control study1, women with
breast cancer (N=324 cases) had an odds ratio of 1.30 (95% confidence interval (CI) 1.14-1.48)
for being a current digoxin user compared to non-users (N=2,546). The association was robust
even after adjustment for prior exposure to menopausal hormone therapy and was not
confounded by indications for use of hormonal therapy. In a nationwide cohort, risk was
examined in 2.1 million women (25.5 million person-years of follow-up through 2008;
N=49,016 breast cancers). Digoxin exposure was obtained through a national prescription
database28 initiated in 1995. The breast cancer incidence rate ratio was 1.39 (95% CI: 1.32-1.46)
in women currently using digoxin, compared to exact age- and calendar-year-adjusted non-using
women. Incidence increased within the first year of digoxin use and continued for the duration
of exposure. Risk in continuing users was high in the first year of exposure, and then dropped to
a nadir at 3 years before rising again. Rate ratio for ER+ (1.35) and untested (1.51) breast cancers
were significantly increased, but for ER- breast cancers (1.20), confidence intervals included
unity. In former users, incidence declined significantly below expected levels in the first year
but rose to expected levels thereafter.
The sodium-potassium pump regulates the transport of a variety of products across the cell
membrane4, providing alternative pathways by which digoxin might affect cancer risk. To
evaluate if the digoxin-associated risk was likely mediated through its effect on ERs, the
incidences of cancers of corpus uteri (uterus), ovary and uterine cervix were compared in
digoxin-exposed and never-exposed women3. Uterus cancers are predominately estrogen-
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
6
sensitive ER+ endometrial cancers, whereas ovarian and cervix cancer are relatively estrogen-
insensitive (with uncommon exceptions). The incidence rate ratio of uterus cancers was
increased 1.48-fold (95% CI: 1.32-1.65) in current digoxin users. In contrast, risks of ovary and
cervix cancers were not increased in current digoxin users (1.06; 0.92-1.22 and 1.00; 0.79-1.25,
respectively). Furthermore, the higher risk of uterus cancer decreased when use of digoxin use
ended.
Risk factors for uterus cancer23 include obesity, a potentially confounding risk factor because it
is shared with cardiovascular disease. However, endometrial cancer risk is decreased in
smokers24, and furthermore, no association was seen between uterus cancer and drugs used for
angina3, which argues against the digoxin effect being related to shared risk factors for
cardiovascular disease. That current digoxin increased the risk of only the estrogen-sensitive
cancers of the breast and uterus, both approximately 1.3- to 1.5-fold, but not ovary or cervix
cancer supports a mechanism mediated by its effect on the ERs.
Estrogen retards the growth on prostate cancer. By analogy, so might digoxin. In drug
screening, digoxin was found to be among the most potent of commonly used drugs in inhibiting
growth of prostate cancer cell lines25. In the same study, the investigators examined risk in men
using digoxin, finding a lower prostate cancer incidence (0.76 (95% CI: 0.61–0.95) compared to
non-users25. Further studies are needed to confirm this result, but the result is consistent with
digoxin exerting an estrogenic effect.
CLINICAL-TRANSLATIONAL ADVANCES
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
7
Other estrogen-mimicking drugs
Other common drugs resemble estrogen. Of most interest is spironolactone, a synthetic 17-
lactone steroid used as a potassium-sparing diuretic in patients with heart failure, cirrhosis,
hypertension and primary aldosteronism, often for prolonged periods26. Spironolactone binds to
and inhibits aldosterone receptors but also to ERs6. Functionally, it is an estrogen agonist27, but
it may also interfere with estrogen metabolism28. Gynecomastia is a common side effect,
occurring in 10% with conventional doses and up to 50% with high doses)29-30. In case reports
patients on spironolactone have been reported to have developed breast cancer31-34, but with
common cancers, case reports have limited value. In one small case-control study (N=302
women with breast cancer), no significant association with spironolactone use was observed35.
This finding should be re-examined in a study with more power. Both digoxin and
spironolactone may be used together in patients with heart disease, complicating analysis.
However, this possibility also raises the prospect of overlapping stimulatory effects on breast
tissue cells and perhaps even higher risks.
One clue to an estrogenic drug effect might be an association of the drug with gynecomastia.
However, gynecomastia may have different causes. Estrogen acts directly on ductal or acinar
tissue. Presumably, digoxin and possibly spironolactone act similarly. However, gynecomastia
may also occur indirectly, via prolactin release from the pituitary7. Antipsychotic and rauwolfia
drugs can cause gynecomastia by blocking dopamine and alpha-adrenergic receptor sites in the
hypothalamus (e.g., phenothiazine derivatives, and opiate derivatives) or by depleting pituitary
catecholamine (e.g., reserpine)7. In the 1980s, considerable concern was raised about reserpine
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
8
and breast cancer risk, but the association was inconclusivee.g.,36. In recent years the risk has
been dismissed as unimportant37 but despite this, reserpine is no longer widely used. A review of
neuroleptic drugs found no increase in breast cancer risk38. Chemically, these drugs differ from
estrogen. With pituitary-induced gynecomastia, galactorrhea may occur7, suggesting that
ductal/acinar cells may differentiate further with hypothalamic/pituitary stimulation than with
estrogen, which might affect differentiation and malignant potential. Finally, drugs such as
cimetidine, a commonly used H2-receptor antagonist, and some (but not all) other anti-ulcer
drugs used to control gastric acidity, may interfere with estrogen metabolism39 and chronic use
has been associated with gynecomastia40. However, but two studies found no association
between cimetidine and breast cancer41,42.
Dietary and over-the-counter phyto-estrogen formulations are sometimes taken for menopausal
symptoms. Compared to prescription medications, they are used in much weaker preparations
and often taken only episodically. There is little evidence they are effective as menopausal
therapy43 but also no evidence that they affect breast44 or uterus cancer risk45.
Public health impact
Despite concern about increasing the risk of breast cancer, digital drugs have important roles in
patient care. Any reconsideration of their use would likely conclude that the benefits of digoxin
for heart disease outweigh the cancer risks. Digoxin use is primarily in the elderly, and hence
this discussion largely concerns post-menopausal breast cancer risk in older women. In
approximately 350,000 Danish women > 70 years old, breast and uterus cancer annual
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
9
incidences are approximately 350 and 90 per 100,000 per year, respectively (data from the
Danish Cancer Registry46). The higher rate ratios for breast and uterus cancers apply only to
2.2% of these women currently using digoxin (data from the Danish Register of Medicinal
Products Statistics23). Thus, in 100,000 women >70 years old, 2200 women would be current
digoxin users, among whom approximately 11 breast (8 expected, based on non-users) and 3
uterus (2 expected) cancers would be observed. The net cancer increase is therefore about 3
breast and 1 uterus cancer cases per 100,000 elderly women per year. While this is only 1% of
all breast cancers in this age group, women using digoxin remain at increased risk for every year
of digoxin use.
Digoxin use in women with cancer
The above presentation focused on cancer incidence. A further concern is the use of digoxin in
women with a history of estrogen-sensitive cancers. Most physicians consider exogenous
estrogen contraindicated in such patients but an absolute prohibition remains controversiale.g. 47-
48. Digoxin use in women with estrogen-sensitive cancers has not been rigorously examined.
While incidence risk is increased with digoxin exposure, this increase may not translate to risk of
death from breast cancer. Mortality from cancer is similar in women who develop breast cancer
while on estrogens and those not on estrogen49-50. Perhaps better medical surveillance is
provided or possibly the biology of the cancers differs. If digoxin-cancer patterns of mortality
parallel those of estrogen, as might be predicted, there may be no direct impact on mortality from
breast cancer, but even so, having both breast cancer and heart disease is likely to cause
increased mortality overall. Similar considerations likely apply to uterus cancer.
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
10
Complicating any analysis will be the use of adjuvant therapy, in particular tamoxifen.
Tamoxifen and other drugs of its type bind to the ER with complex results. They inhibit
attachment of estrogen on ductal and acinar cells51 and thus could also block digoxin effect on
mammary tissue. However, effects of different drugs within this class vary. In particular,
tamoxifen increases the proliferation of endometrial cells and increases the risk of endometrial
cancer and sarcomas of the uterus, whereas other drugs in the same class apparently do not52-53.
In recently years, aromatase inhibitors, a different class of drug, have become widely used in the
treatment of post menopausal patients. These agents block estrogen production but leave the
ERs unaffected and without competition by natural estrogens54. Thus, digoxin would have full
license to interact with the ER and stimulate proliferation, assuming its effect is mediated
through ER binding. If digoxin use is shown to affect breast cancer prognosis adversely, then
use of tamoxifen as adjunct therapy might be considered.
In conflict with concern about an increasing risk, some investigators hypothesize digoxin might
benefit women with breast cancer. In vitro, it inhibits cell adhesion or proliferation in breast
cancer cell cultures55,56 and several different molecular pathways have been porposede.g,57-58.
One retrospective study (32 women on digoxin with mortality as the outcome) suggested it might
be beneficial59. Regarding cell culture systems, drug doses may be well in excess of those
physiologically tolerated by human subjects and hence toxic both to cells and the patient.
However, estrogen itself, at very high doses, can also inhibit breast cancer cell lines in vitro60.
Summary
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
11
Current digoxin use increases the incidence of estrogen-dependent breast and uterus cancers,
with rate ratios reverting to the null when exposure stops. Since only current use increases the
incidence, the mechanism may be that of a promoter, i.e., digoxin enhancing proliferation of
nascent tumors rather than inducing new tumors. On theoretical grounds (and anecdotal data),
other estrogen-mimicking drugs may have similar effects. Of particular concern are the
potassium-sparing diuretics. Despite cancer risks, the use of digital drugs may be medically
indicated because their cardiac benefits likely exceed cancer risks. However, the impact of
digoxin use on women with active estrogen-sensitive cancers has yet to be evaluated. It is
possible that digoxin, and perhaps other estrogen-mimicking drugs, could affect extant breast and
uterus cancers adversely. Physicians treating women with existing cancers may wish to consider
using alternative therapies, where possible, and should be especially alert to possible breast or
uterus cancer symptoms when digoxin use is clinically indicated.
Acknowledgements: Dr. Louise Brinton, National Cancer Institute, Bethesda, MD and Prof.
Niels Kroman, Rigshospitalet, Copenhagen, Denmark provided helpful comments on this
manuscript. Support for this paper was provided by the Danish Cancer Society (Kræftens
Bekæmpelse, Grant number R40-A1857-11-S2)) without restriction its contents or any role in the
decision to submit.
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
12
References 1. Ahern TP, Lash TL, Sørensen HT, Petersen L: Digoxin treatment is associated with an
increased incidence of breast cancer: a population-based case control study. Breast Cancer
Research 2008; 10:R102.
2. Biggar RJ, Wohlfahrt J, Oudin A, Hjuler T, Mads Melbye. Digoxin use and the risk of breast
cancer in women. J Clin Oncol 2011;29:2165-70.
3. Biggar RJ, Wohlfahrt J, Melbye M. Digitalis and the risk of gynecological cancer in women.
Int J Cancer. 2011 Sep 12. 10.1002/ijc.26424. (Epub).
4. McDonough AA, Velotta JB, Schwinger RH, Philipson KD, Farley RA. The cardiac sodium
pump: structure and function. Basic Res Cardiol 2002;97 Supplement 1: I19-24.
5. Rifka SM, Pita JC Jr, Loriaux DL. Mechanism of interaction of digitalis with estradiol
binding sites in rat uteri. Endocrinology 1976;99:1091-6.
6. Rifka SM, Pita JC, Vigersky RA, Wilson YA, Loriaux DL: Interaction of digitalis and
spironolactone with human sex steroid receptors. J Clin Endocrinol Metab 1978;46:338-44.
7. Dickey RP, Stone SC. Drugs that affect the breast and lactation. Clin Obstet Gynecol
1975:18:95-111.
8. Braustein GD. Gynecomastia. N Engl J Med 1993;328:490-5.
9. Colditz GA, Baer HJ, Tamimi RM. Breast Cancer. In Schottenfeld D and Fraumeni JF Jr.,
Editors: Cancer Epidemiology and Prevention. New York. Oxford University Press, Inc. 2006:
p. 995-1012.
10. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Martin L, et al. Breast
cancer after use of estrogen plus progestin in postmenopausal women. New Engl J Med
2009;360:573-87.
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
13
11. Dietel M. Hormone replacement therapy (HRT), breast cancer and tumor pathology.
Maturitas 2010;65:183-9.
12. Furness S, Roberts H, Marjoribanks J, Lethaby A, Hickey M, Farquhar C. Hormone therapy
in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev
2009; CD000402.
13. Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of
endometrial and breast cancer. Steroids 2000; 65:659-64.
14. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Menopausal
hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev
2007;16:2548–56.
15. Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the
Million Women Study. Lancet 2007;369:1703–10.
16. Lacey JV, Jr., Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, et al.
Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP
Diet and Health Study Cohort. J Natl Cancer Inst 2006;98:1397–405.
17. Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A. Smoking habit,
immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical
carcinogenesis: a review of the literature. Gynecol Endocrinol 2011;27:597-604.
18. Stenkvist B, Pengtsson E, Dahlqvist B, Eriksson O, Jarkrans T, Nordin B. Cardiac
glycosides and breast cancer, revisited. N Engl J Med 1982;306:484.
19. Friedman GD. Digitalis and breast cancer. Lancet 1984;2:875.
20. Haux J, Klepp O, Spigset O, Tretli S. Digitoxin medication and cancer; case control and
internal dose-response studies. BMC Cancer 2001;1:11.
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
14
21. Lenfant-Pejovic MH, Mlika-Cabanne N, Bouchardy C, Auquier A. Risk factors for male
breast cancer: a Franco-Swiss case-control study. Int J Cancer 1990;45:661-5.
22. Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factors for male breast
cancer--a case-control study from Scandinavia. Acta Oncol 2001;40:467-71.
23. Gaist D, Sorensen HT and Hallas J. The Danish prescription registries. Dan Med Bull
1997,44,445–448.
24. Tinelli A, Vergara D, Martignago R, Leo G, Malvasi A, Tinelli R. Hormonal carcinogenesis
and socio-biological development factors in endometrial cancer: a clinical review. Acta Obstet
Gynecol Scand 2008; 87: 1101-13.
25. Platz EA,Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, et al. A novel
two-stage transdisciplinary study identifies digoxin as a possible drug for prostate cancer
treatment. Cancer Discovery 2011:1:69-77.
26. Horisberger JD, Giebisch G. Potassium-sparing diuretics. Ren Physiol 1987;10:198–220.
27. Barbato JC. Estrogen receptor activation--good, aldosterone receptor blockade--beneficial,
communication between receptors...priceless. Hypertension 2007;50:297-8.
28. Satoh T, Munakata H, Fujita K, Itoh S, Kamataki T, Yoshizawa I. Studies on the
interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to
induce gynecomastia on the oxidation of estradiol at C-2 or C-17. Biol Pharm Bull 200;26:695-
700.
29. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy
and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820–825.
30. Bridgett A. Haynes BA, Mookadam F. Male Gynecomastia. Mayo Clin Proc 2009; 84: 672.
31. Jick H, Armstrong B. Letter: Breast cancer and spironolactone. Lancet 1975;2:368-9.
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
15
32. Loube SD, Quirk RA. Letter: Breast cancer associated with administration of
spironolactone. Lancet 1975;1:1428-9.
33. Lamy O, Elmiger H, Fiche M, Bauer J, Livio F. Acquired hemophilia as first manifestation
of breast carcinoma in a man under long-term spironolactone therapy. Int J Clin Oncol
2004;9:130-3.
34. Stierer M, Spoula H, Rosen HR [Breast cancer in the male--a retrospective analysis of 15
cases]. Onkologie 1990;13:128-31. [German]
35. Danielson DA, Jick H, Hunter JR, Stergachis A, Madsen S. Nonestrogenic drugs and breast
cancer. Am J Epidemiol 1982;116:329-32.
36. Horwitz RI, Feinstein AR. Exclusion bias and the false relationship of reserpine and breast
cancer. Arch Intern Med 1985;145:1873-5.
37. Grossman E, Messerli FH, Goldbourt U. Carcinogenicity of antihypertensive therapy. Curr
Hypertens Rep 2002;4:195-201.
38. Dalton SO, Johansen C, Poulsen AH, Nørgaard M, Sørensen HT, McLaughlin JK, et al.
Cancer risk among users of neuroleptic medication: a population-based cohort study. Br J Cancer
2006;95:934-9.
39. Galbraith RA, Michnovicz JJ. The effects of cimetidine on the oxidative metabolism of estradiol. N
Engl J Med 1989;321:269-74.
40. García Rodríguez LA, Jick H. Risk of gynaecomastia associated with cimetidine,
omeprazole, and other antiulcer drugs. BMJ 1994;308:503-6.
41. Rossing MA, Scholes D, Cushing-Haugen KL, Voigt LF. Cimetidine use and risk of
prostate and breast cancer. Cancer Epidemiol Biomarkers Prev 2000;9:319-23.
42. Habel LA, Levin TR, Friedman GD. Cimetidine use and risk of breast, prostate, and other
cancers. Pharmacoepidemiol Drug Saf 2000;9:149-55.
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
16
43. Tempfer CB, Froese G, Heinze G, Bentz EK, Hefler LA, Huber JC. Side effects of
phytoestrogens: a meta-analysis of randomized trials. Am J Med 2009;122:939-46.e9.
44. This P, de Cremoux P, Leclercq G, Jacquot Y. A critical view of the effects of
phytoestrogens on hot flashes and breast cancer risk. Maturitas 2011;70:222-6.
45. Bandera EV, Williams MG, Sima C, Bayuga S, Pulick K, Wilcox H, et al. Phytoestrogen
consumption and endometrial cancer risk: a population-based case-control study in New Jersey.
Cancer Causes Control 2009;20:1117-27.
46. Storm HH, Michelsen EV, Clemmensen IH, Pihl J: The Danish Cancer Registry—history,
content, quality, and use. Dan Med Bull 1997;44:535-9.
47. Brennan ME, Houssami N. Overview of long term care of breast cancer survivors. Maturitas
2011;69:106-12.
48. Maclennan AH. HRT in difficult circumstances: are there any absolute contraindications?
Climacteric 2011;14:409-17.
49. Norman SA, Weber AL, Localio AR, Marchbanks PA, Ursin G, Strom BL, et al. Hormone
therapy and fatal breast cancer. Pharmacoepidemiol Drug Saf 2010;19:440-7.
50. Chen W, Petitti D, Geiger A. Mortality following development of breast cancer while using
oestrogen or oestrogen plus progestin: a computer record-linkage study. Br J Cancer
2005;93:392–398.
51. Rivera-Guevara C, Camacho J. Tamoxifen and its new derivatives in cancer research.
Recent Pat Anticancer Drug Discov 2011;6:237-45.
52. Pinkerton JV, Goldstein SR. Endometrial safety: a key hurdle for selective estrogen
receptor modulators in development. Menopause 2010;17:642-53.
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
17
53. Williams-Brown MY, Salih SM, Xu X, Veenstra TD, Saeed M, Theiler SK, et al. The effect
of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid
Biochem Mol Biol 2011;126:78-86.
54. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and
breast cancer. J Steroid Biochem Mol Biol 2011;125:13-22.
55. Stenkvist B. Is digitalis a therapy for breast carcinoma? Oncol Rep 1999;6:493-6.
56. Haux J. Digitoxin is a potential anticancer agent for several types of cancer. Med
Hypotheses 1999;53:543-8.
57. Kometiani P, Liu L, Askari A. Digitalis-induced signaling by Na+/K+-ATPase in human
breast cancer cells. Mol Pharmacol. 2005:67:929-36.
58. Winnicka K, Bielawski K, Bielawska A. Synthesis and cytotoxic activity of G3 PAMAM-
NH(2) dendrimer-modified digoxin and proscillaridin A conjugates in breast cancer cells.
Pharmacol Rep 2010:62:414-23.
59. Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Claeson P. Cytotoxicity of
digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs 2001;12:475-
83.
60. Reddel RR, Sutherland RL. Effects of pharmacological concentrations of estrogens on
proliferation and cell cycle kinetics of human breast cancer cell lines in vitro. Cancer Res
1987;15;47:5323-9.
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
18
Figure 1. Speculation concerning the pathogenesis by which estrogen and estrogenic compounds
might affect estrogen-sensitive tissues, including nascent cancer cells.
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389
Published OnlineFirst February 24, 2012.Clin Cancer Res Robert J Biggar cancers: risks and possible therapeutic implicationsMolecular Pathways: Digoxin use and the estrogen-sensitive
Updated version
10.1158/1078-0432.CCR-11-1389doi:
Access the most recent version of this article at:
Manuscript
Authoredited. Author manuscripts have been peer reviewed and accepted for publication but have not yet been
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Subscriptions
Reprints and
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2012/02/24/1078-0432.CCR-11-1389To request permission to re-use all or part of this article, use this link
Research. on May 21, 2018. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on February 24, 2012; DOI: 10.1158/1078-0432.CCR-11-1389